期刊文献+

梁冰中医辨治真性红细胞增多症经验 被引量:1

Experience of LIANG Bing in treating polycythemia vera based on syndrome differentiation
原文传递
导出
摘要 真性红细胞增多症为慢性骨髓增殖性疾病,临床治疗多选用干扰素、化疗药物等,治疗并发症多,患者难以坚持治疗,芦可替尼虽已批准临床应用,但因其价格昂贵,多数国内患者难以承受。梁冰教授运用中药活血解毒、攻补分层、选用虫类药物治疗常获良效,特将经验分享。 As a chronic myeloproliferative disease, polycythemia vera is treated by interferon, chemotherapy drug etc in clinic, but there are many complications, the patients are difficult to adhere to treatment. Although Ruxolitinib has been approved in clinical application, but because of its high prices, most of the domestic patients are unbearable. Professor LIANG Bing selects insect drugs often get good results in treating polycythemia vera by using Chinese medicine to promoting blood circulation and detoxication, reinforcement and elimination inseparation, especially to share experiences.
作者 李慧 代喜平 李达 LI Hui;DAI Xi-ping;LI Da(Guangdong Provincial Hospital of Chinese Medicine,Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine,Guangzhou510120,China)
机构地区 广东省中医院
出处 《中华中医药杂志》 CAS CSCD 北大核心 2018年第11期5008-5011,共4页 China Journal of Traditional Chinese Medicine and Pharmacy
基金 中医药强省专项-2015年广东省第二批名中医师承项目 2015年全国名老中医梁冰教授学术思想与临证经验整理(No.2014KT1702)
关键词 真性红细胞增多症 名医经验 梁冰 Polycythemia vera Experience of national famous TCM expert LIANG Bing
  • 相关文献

参考文献4

二级参考文献19

  • 1梁冰,李达.血液病[M].第2版.北京:人民卫生出版社,2006:249.
  • 2Pikman Y, Lee BH, Mercher T, et al.MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia [ J ]. PLoS Med, 2006, 3 ( 7 ) : e270.
  • 3Nangalia J, Massie CE, Baxter EJ, et al.Somatic CALR mutalions in myeloproliferative neoplasms with nonmutated JAK2 [ J]. N Engl J Med, 2013, 369: 2391-2405.
  • 4Klampfl T, Gisslinger H, Hamtyunyan AS, et al.Somatic mutations of calreticulin in myeloproliferative neoplasms [ J ]. N Engl J Med, 2013, 369 ( 25 ) : 2379-2390.
  • 5Constantinescu SN, Vainchenker W. Small-molecule inhibitors in myeloproliferative neoplasms: are we aiming for the right targets? [ J ]. Hematology Am Soc Hematol Educ Program, 2012, 2012: 553-560.
  • 6Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2- V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice [ J ]. Blood, 2008, 111 ( 8 ) : 3931-3940.
  • 7Tefferi A, Guglielmelli P, Lasho TL, et al.CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients [ J ]. Leukemia, 2014, 28 ( 7 ) : 1494-1500.
  • 8Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment [ J ]. Blood, 2009, 113 ( 13 ) : 2895-2901.
  • 9Passamonti F, Cervantes F, Vannucehi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT ( International Working Group for Myeloproliferative Neoplasms Research and Treatment ) [ J ]. Blood, 2010, 115(9) : 1703-1708.
  • 10Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status [ J ]. J Clin Oncol, 2011, 29 ( 4 ) : 392-397.

共引文献19

同被引文献5

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部